Indications and uses
This Homeopathic product of natural source helps relieve pain, diarrhea, cramps, and nausea.
This Homeopathic product of natural source helps relieve pain, diarrhea, cramps, and nausea.
Adults: Allow 3 pellets to dissolve under the tongue three times a day or as directed by a health professional. For adult use only. Do not exceed recommended dosage.
China 3X
Bryonia alba 4X
Chamomilla 4X
Colocynthis 4X
Ipeca 4X
Belladonna 3X
Potentilla anserina 1X
Manufactured according to the Homeopathic Pharmacopoeia of the United States (HPUS)
Helps relieve symptoms due to Diarrhea
This Homeopathic product of natural source helps relieve pain, diarrhea, cramps, and nausea.
If symptoms persist or worsen, discontinue use and contact a health professional.
As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.
Keep this and all medications out of reach of children.
Adults: Allow 3 pellets to dissolve under the tongue three times a day or as directed by a health professional.
For adult use only. Do not exceed recommended dosage.
Do not use if cap seal is broken.
Homeolab USA Inc., 3025 De L'Assomption Blvd., Montreal, QC H1N 2H2 Canada
PRODUCT OF CANADA
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60512-9055-1 | 2025-12-27 | C162847 | 48780-1 | 9d75b9cf-da00-f424-e053-dadaa90a57ce | DRUG FACTS |
| 60512-9055-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9cf-da00-f424-e053-dadaa90a57ce | DRUG FACTS |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60512-9055 | DIARRHEA RELIEF (CHINA, BRYONIA ALBA, CHAMOMILLA, COLOCYNTHIS, IPECA, BELLADONNA, POTENTILLA ANSERINA) PELLET [HOMEOLAB USA INC.] | 2 | Legacy NDC | 20131115_62d4b636-3144-4f41-8f30-a7d8ccf367e7.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ATROPA BELLADONNA WHOLE | ACTIVE INGREDIENT | DSV74G1P2J | 2 | |
| BRYONIA ALBA ROOT | ACTIVE INGREDIENT | T7J046YI2B | 2 | |
| CINCHONA OFFICINALIS BARK | ACTIVE INGREDIENT | S003A158SB | 2 | |
| CITRULLUS COLOCYNTHIS FRUIT PULP | ACTIVE INGREDIENT | 23H32AOH17 | 2 | |
| IPECAC | ACTIVE INGREDIENT | 62I3C8233L | 2 | |
| MATRICARIA CHAMOMILLA WHOLE | ACTIVE INGREDIENT | 2Z4LRR776S | 2 | |
| POTENTILLA ANSERINA WHOLE | ACTIVE INGREDIENT | I5G2JR395W | 2 | |
| ATROPA BELLADONNA WHOLE | ACTIVE MOIETY | DSV74G1P2J | 2 | |
| BRYONIA ALBA ROOT | ACTIVE MOIETY | T7J046YI2B | 2 | |
| CINCHONA OFFICINALIS BARK | ACTIVE MOIETY | S003A158SB | 2 | |
| CITRULLUS COLOCYNTHIS FRUIT PULP | ACTIVE MOIETY | 23H32AOH17 | 2 | |
| IPECAC | ACTIVE MOIETY | 62I3C8233L | 2 | |
| MATRICARIA CHAMOMILLA WHOLE | ACTIVE MOIETY | 2Z4LRR776S | 2 | |
| POTENTILLA ANSERINA WHOLE | ACTIVE MOIETY | I5G2JR395W | 2 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60512-9055 | 60512-9055-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CINCHONA OFFICINALIS BARK | S003A158SB | ACTIB |
| BRYONIA ALBA ROOT | T7J046YI2B | ACTIB |
| MATRICARIA CHAMOMILLA WHOLE | 2Z4LRR776S | ACTIM |
| CITRULLUS COLOCYNTHIS FRUIT PULP | 23H32AOH17 | ACTIB |
| IPECAC | 62I3C8233L | ACTIB |
| ATROPA BELLADONNA WHOLE | DSV74G1P2J | ACTIM |
| POTENTILLA ANSERINA WHOLE | I5G2JR395W | ACTIB |
| SUCROSE | C151H8M554 | IACT |
| LACTOSE | J2B2A4N98G | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 46fbf8b9-89a6-761c-e063-6294a90afa72 | 62d4b636-3144-4f41-8f30-a7d8ccf367e7 | 2025-12-27 | Warnings | 62d4b636-3144-4f41-8f30-a7d8ccf367e7 |
Adverse event summaries are temporarily unavailable. Other product information remains available.